- 1、本文档共38页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
* * Key Point: Traditional “bottom-up” therapy as recommended by the American College of Gastroenterology (ACG) in its UC practice guidelines utilizes conventional medications such as 5-aminosalicylates (5-ASAs) as first-line therapies, while reserving more aggressive agents (eg, infliximab, IV steroids, cyclosporine) for more severe and/or refractory patients. Background: Current therapeutic paradigms recommend 5-ASA agents as first-line therapy for patients with mild to moderate UC.1 Oral corticosteroids are typically reserved for patients who do not respond to oral 5-ASA agents with or without topical agents, or for patients who need rapid improvement.1 Infliximab has demonstrated efficacy in patients who have moderate to severe UC despite receiving therapy with conventional agents.2 Aggressive medical therapies (IV corticosteroids, cyclosporine) are generally reserved for patients with severe or fulminant UC not responding to maximal oral doses of 5-ASAs and corticosteroids.1 References1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99(7):1371-1385. 2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476. * * Key Point: Although preliminary data in Crohn’s disease suggest that reversing the traditional “step-up” treatment pyramid in favor of “top-down” therapy in newly diagnosed patients may result in early disease stabilization and disease modification, this approach has not been well studied in UC. Background: ? The use of a “top-down” approach in UC has not been studied prospectively to date. Preliminary, 2-year, open-label data in Crohn’s disease have demonstrated that initiating aggressive medical therapy (ie, infliximab) early in the course of disease may result in better outcomes such as improved mucosal healing and redu
您可能关注的文档
- 周围神经病ppt参考课件.ppt
- CT、MRI增强检查注意事项及造影剂不良反应ppt参考课件.ppt
- COPD患者雾化吸入装置的使用法ppt参考课件.ppt
- Beckwith-Wiedemann综合征ppt参考课件.ppt
- 围术期高血压管理专家共识ppt参考课件.ppt
- 18项核心制度与医疗风险防范ppt参考课件.ppt
- infant flow sipap培训ppt参考课件.ppt
- MERS中东呼吸系统综合征ppt参考课件.ppt
- ICU非计划性拔管原因分析与处理ppt参考课件.ppt
- ICU常用实验室检查及临床意义ppt参考课件.ppt
- 专卖店促销员销售与成交技巧培训课件(34P).pptx
- 红色商务风新员工入职销售技巧知识培训课件(34P).pptx
- 专卖店商场销售员销售与成交技巧培训课件(34P).pptx
- 小区物业保安法律知识培训课件(28P).pptx
- 专卖店销售员轻松成交技巧培训(34P).pptx
- 轻松成交客户新员工入职通用销售技巧知识培训(34P).pptx
- 2024年初级《银行业法律法规与综合能力》考前必刷必练题库500题(含真题、必会题).docx
- 2024年“新安法知多少”知识竞赛题库及答案(最新版).docx
- 2024年30秒毕业生面试工作自我介绍.docx
- 2024年《医务人员礼仪培训》心得体会.docx
文档评论(0)